304 related articles for article (PubMed ID: 18430361)
41. K252a prevents nigral dopaminergic cell death induced by 6-hydroxydopamine through inhibition of both mixed-lineage kinase 3/c-Jun NH2-terminal kinase 3 (JNK3) and apoptosis-inducing kinase 1/JNK3 signaling pathways.
Pan J; Wang G; Yang HQ; Hong Z; Xiao Q; Ren RJ; Zhou HY; Bai L; Chen SD
Mol Pharmacol; 2007 Dec; 72(6):1607-18. PubMed ID: 17855652
[TBL] [Abstract][Full Text] [Related]
42. Biochemical alteration in cerebrospinal fluid precedes behavioral deficits in Parkinsonian rats induced by 6-hydroxydopamine.
Lin JW; Shih CM; Chen YC; Lin CM; Tsai JT; Chiang YH; Shih R; Chiu PL; Hung KS; Yeh YS; Wei L; Chiu WT; Yang LY
Surg Neurol; 2009 Dec; 72 Suppl 2():S55-65; discussion S65. PubMed ID: 19944827
[TBL] [Abstract][Full Text] [Related]
43. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats.
Pang Y; Lin S; Wright C; Shen J; Carter K; Bhatt A; Fan LW
Neuroscience; 2016 Mar; 318():157-65. PubMed ID: 26777890
[TBL] [Abstract][Full Text] [Related]
44. PPAR-γ agonist pioglitazone reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson's disease.
Machado MMF; Bassani TB; Cóppola-Segovia V; Moura ELR; Zanata SM; Andreatini R; Vital MABF
Pharmacol Rep; 2019 Aug; 71(4):556-564. PubMed ID: 31132685
[TBL] [Abstract][Full Text] [Related]
45. The kappa opioid agonist U50,488 potentiates 6-hydroxydopamine-induced neurotoxicity on dopaminergic neurons.
Marin C; Bové J; Serrats J; Cortés R; Mengod G; Tolosa E
Exp Neurol; 2005 Jan; 191(1):41-52. PubMed ID: 15589511
[TBL] [Abstract][Full Text] [Related]
46. Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro.
Mu X; He G; Cheng Y; Li X; Xu B; Du G
Pharmacol Biochem Behav; 2009 Jun; 92(4):642-8. PubMed ID: 19327378
[TBL] [Abstract][Full Text] [Related]
47. Role of glycine receptors and glycine release for the neuroprotective activity of bilobalide.
Kiewert C; Kumar V; Hildmann O; Hartmann J; Hillert M; Klein J
Brain Res; 2008 Mar; 1201():143-50. PubMed ID: 18325484
[TBL] [Abstract][Full Text] [Related]
48. D-beta-hydroxybutyrate inhibits the apoptosis of PC12 cells induced by 6-OHDA in relation to up-regulating the ratio of Bcl-2/Bax mRNA.
Cheng B; Yang X; Hou Z; Lin X; Meng H; Li Z; Liu S
Auton Neurosci; 2007 Jul; 134(1-2):38-44. PubMed ID: 17369104
[TBL] [Abstract][Full Text] [Related]
49. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats.
Wang JY; Wu JN; Cherng TL; Hoffer BJ; Chen HH; Borlongan CV; Wang Y
Brain Res; 2001 Jun; 904(1):67-75. PubMed ID: 11516412
[TBL] [Abstract][Full Text] [Related]
50. Activation of p38 MAPK in the substantia nigra leads to nuclear translocation of NF-kappaB in MPTP-treated mice: implication in Parkinson's disease.
Karunakaran S; Ravindranath V
J Neurochem; 2009 Jun; 109(6):1791-9. PubMed ID: 19457134
[TBL] [Abstract][Full Text] [Related]
51. Neuroprotective and behavioural assessments of an imidazolium compound (DBZIM) in a rat model of Parkinson's disease induced by 6-OHDA.
Chan HH; Kumar S; Zhuo L
Eur J Pharmacol; 2013 Sep; 715(1-3):405-13. PubMed ID: 23652161
[TBL] [Abstract][Full Text] [Related]
52. Effect of PACAP in 6-OHDA-induced injury of the substantia nigra in intact young and ovariectomized female rats.
Reglödi D; Lubics A; Kiss P; Lengvári I; Gaszner B; Tóth G; Hegyi O; Tamás A
Neuropeptides; 2006 Aug; 40(4):265-74. PubMed ID: 16904179
[TBL] [Abstract][Full Text] [Related]
53. Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression.
Sadeghian M; Marinova-Mutafchieva L; Broom L; Davis JB; Virley D; Medhurst AD; Dexter DT
J Neuroimmunol; 2012 May; 246(1-2):69-77. PubMed ID: 22498097
[TBL] [Abstract][Full Text] [Related]
54. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease.
Vernon AC; Palmer S; Datla KP; Zbarsky V; Croucher MJ; Dexter DT
Eur J Neurosci; 2005 Oct; 22(7):1799-806. PubMed ID: 16197521
[TBL] [Abstract][Full Text] [Related]
55. [Autophagy is involved in 6-OHDA-induced dopaminergic cell death].
Xia LP; Li LY; Fei XF; Liang ZQ
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec; 30(12):2649-51. PubMed ID: 21177170
[TBL] [Abstract][Full Text] [Related]
56. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
[TBL] [Abstract][Full Text] [Related]
57. Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue.
Andres RH; Huber AW; Schlattner U; Pérez-Bouza A; Krebs SH; Seiler RW; Wallimann T; Widmer HR
Neuroscience; 2005; 133(3):701-13. PubMed ID: 15890457
[TBL] [Abstract][Full Text] [Related]
58. PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity.
Carrasco E; Casper D; Werner P
J Neurosci Res; 2007 Nov; 85(14):3109-17. PubMed ID: 17868147
[TBL] [Abstract][Full Text] [Related]
59. Edaravone protects neurons in the rat substantia nigra against 6-hydroxydopamine-induced oxidative stress damage.
Liu X; Shao R; Li M; Yang G
Cell Biochem Biophys; 2014 Nov; 70(2):1247-54. PubMed ID: 24948472
[TBL] [Abstract][Full Text] [Related]
60. A proteomic approach in the study of an animal model of Parkinson's disease.
De Iuliis A; Grigoletto J; Recchia A; Giusti P; Arslan P
Clin Chim Acta; 2005 Jul; 357(2):202-9. PubMed ID: 15946658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
